Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets with potential utility across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions. Headquartered in Boston, Massachusetts, Centessa was recognized as a Great Place to Work® in 2026.
Hiring activity
- Open roles
- 1
- Posted in the last 30 days
- 2
Updated 9h ago
What Centessa Pharmaceuticals says about its culture
What Centessa Pharmaceuticals says it offers, drawn from its own website.
Check if you fitOpens the career fit test.
Our mission is to discover and develop medicines that are transformational for patients.
Innovation
“We seek out innovation.”Source
Integrity
“We conduct our work with integrity.”Source
Accountability
“We are accountable.”Source
Collaboration
“We value collaboration.”Source
Quoted from Centessa Pharmaceuticals's own website. TeaKo does not verify these claims.
Latest openings
1 open role at Centessa Pharmaceuticals. Members see each one.
